- Home
- KLRS vs ATCX Comparison
KLRS vs ATCX Comparison
Compare KLRS & ATCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | ATCX |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 48.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KLRS | ATCX |
|---|---|---|
| Price | $9.50 | $9.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $20.67 | N/A |
| AVG Volume (30 Days) | 84.4K | ★ 134.0K |
| Earning Date | 02-24-2026 | 03-16-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $367,030.00 |
| Revenue This Year | N/A | $109,631.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $4.80 |
| 52 Week High | $12.90 | $47.16 |
Technical Indicators
Market Signals| Indicator | KLRS | ATCX |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 54.88 |
| Support Level | $9.55 | $9.18 |
| Resistance Level | $10.47 | $14.01 |
| Average True Range (ATR) | 0.83 | 1.82 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 56.03 | 37.07 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corporation, is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.